DiaGenic's method can be used to detect Alzheimer's disease.

The results from the project in cooperation with IMGM Laboratories using a commercial micro-array platform from Applied Biosystems confirm that DiaGenic's method can be used to detect Alzheimer's disease.

The results from the project in cooperation with IMGM Laboratories using a commercial micro-array platform from Applied Biosystems confirm that DiaGenic's method can be used to detect Alzheimer's disease.

In a notice to the Stock Exchange dated 22 September 2005 DiaGenic announced its findings from a pilot study on Alzheimer's disease.

The study has now been continued in a comprehensive project at the external service laboratory IMGM in Germany, using a commercial micro-array platform from Applied Biosystems. The first analytical work on this larger study has now been completed and the project has been confirmed as a success. Praveen Sharma, Director of Technology in DiaGenic, comments in connection with the publication of the results: "The first results from this comprehensive project confirm that DiaGenic's method can be used to detect Alzheimer's disease. This is an important milestone in the development of a product prototype."

DiaGenic cooperates with the Norwegian University of Life Sciences ("UMB") in connection with the FUGE-projects. UMB has considerable expertise in the analysis of micro-array data. Are Aastveit, Professor of Statistics at UMB, comments: "The results from the Alzheimer's study support DiaGenic's concept. The results obtained were based on a large number of samples, and recognised statistical methods were used in analysis and validation of the results."

In recent months DiaGenic has recorded increased international acceptance of the diagnostic concept involving the use of blood as a sample material combined with analysis of gene expression. Particularly for conditions such as Alzheimer's disease and other diseases of the brain and nervous system it is in practice impossible to use sample material from the site of the disease. A number of scientific articles by external researchers also support this concept. A list of such articles and a fact sheet on Alzheimer's disease is available on the website www.diagenic.com under "Investor relations".

Håkon Sæterøy, Chairman
Telephone: +47 9269 5175
haakon.saeteroy@diagenic.com

Associated companies: